Abstract:Background: Although Basidiomycota produce pharmaceutically and ecologically relevant natural products, knowledge of how they coordinate their primary and secondary metabolism is virtually non-existent. Upon transition from vegetative mycelium to carpophore formation, mushrooms of the genus Psilocybe use L-tryptophan to supply the biosynthesis of the psychedelic tryptamine alkaloid psilocybin with the scaffold, leading to a strongly increased demand for this particular amino acid as this alkaloid may account for up to 2% of the dry mass. Using Psilocybe mexicana as our model and relying on genetic, transcriptomic, and biochemical methods, this study investigated if L-tryptophan biosynthesis and degradation in P. mexicana correlate with natural product formation. Results: A comparative transcriptomic approach of gene expression in P. mexicana psilocybin non-producing vegetative mycelium versus producing carpophores identified the upregulation of L-tryptophan biosynthesis genes. The shikimate pathway genes trpE1, trpD, and trpB (encoding anthranilate synthase, anthranilate phosphoribosyltransferase, and L-tryptophan synthase, respectively) were upregulated in carpophores. In contrast, genes idoA and iasA, encoding indole-2,3-dioxygenase and indole-3-acetaldehyde synthase, i.e., gateway enzymes for L-tryptophan-consuming pathways, were massively downregulated. Subsequently, IasA was heterologously produced in Escherichia coli and biochemically characterized in vitro. This enzyme represents the first characterized microbial L-tryptophan-preferring acetaldehyde synthase. A comparison of transcriptomic data collected in this study with prior data of Psilocybe cubensis showed species-specific differences in how L-tryptophan metabolism genes are regulated, despite the close taxonomic relationship. Conclusions: The upregulated L-tryptophan biosynthesis genes and, oppositely, the concomitant downregulated genes encoding L-tryptophan-consuming enzymes reflect a well-adjusted cellular system to route this amino acid toward psilocybin production. Our study has pilot character beyond the genus Psilocybe and provides, for the first time, insight in the coordination of mushroom primary and secondary metabolism.

Exploring the biocatalysis of psilocybin and other tryptamines: Enzymatic pathways, synthetic strategies, and industrial implications

Β-Methyltryptamine Provoking the Crucial Role of Strictosidine Synthase Tyr151-OH for Its Stereoselective Pictet−Spengler Reactions to Tryptoline-type Alkaloids

Evaluation of TrpM and PsiD substrate promiscuity reveals new biocatalytic capabilities

New frontiers in the biosynthesis of psychoactive specialized metabolites

Genetic regulation of L-tryptophan metabolism in Psilocybe mexicana supports psilocybin biosynthesis

Pharmacological and behavioural effects of tryptamines present in psilocybin‐containing mushrooms

Optimized psilocybin production in tryptophan catabolism‐repressed fungi

Biosynthesis and synthetic biology of psychoactive natural products

Substrate recognition by the 4‐hydroxytryptamine kinase PsiK in psilocybin biosynthesis

Expanding the application of tryptophan: Industrial biomanufacturing of tryptophan derivatives

The biosynthetic pathway of the hallucinogen mescaline and its heterologous reconstruction

"In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli"

Methyl transfer in psilocybin biosynthesis

A Novel Synthetic Route Towards Acyloxymethyl Prodrugs of Psilocin and Related Tryptamines

Enzymatic and chemo-enzymatic approaches towards natural and non-natural alkaloids: indoles, isoquinolines, and others.

Advances in the Microbial Synthesis of 5-Hydroxytryptophan

Advances in Metabolic Engineering of Saccharomyces Cerevisiae for Terpenoids Biosynthesis

A modular and synthetic biosynthesis platform for de novo production of diverse halogenated tryptophan-derived molecules

Advances in the microbial synthesis of the neurotransmitter serotonin

Pharmacokinetics of Psilocybin, a Tryptamine Alkaloid in Magic Mushroom (Psilocybe cubensis): A Systematic Review

Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases